Moviegoing at AMC theaters might be a bit more expensive — or cheaper — depending on where you want to sit.

The theater chain just announced its new Sightline program, featuring three different pricing tiers. The value section is made up of seats in the front rows, to be discounted.

The standard section, the most common ones, will remain traditionally priced, and preferred seats, typically the most prized ones in the middle of the auditorium, will charge a premium rate. 

Moviegoers will get a detailed seating map with the different prices while purchasing on the web, through the AMC app, or at the box office.

Eliot Hamlisch, EVP and CMO of AMC Theaters, noted that it fits with the kind of changes that have already taken place in entertainment.

"Sightline at AMC more closely aligns with AMC's seat pricing approach to that of many other entertainment venues, offering experienced-based pricing and another way for moviegoers to find value at the movies," he said in a statement.

For those who might not be the biggest fans of the change, the Sightline program will only be in effect for films showing after 4 p.m. However, AMC noted that its goal is to expand the program to all of its locations, including its dine-in theaters, by the end of 2023.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More